Corcept Therapeutics: The ROSELLA Trial Presents A Major Win For The Company
Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal. See why we still consider ...
Broadsheet1m
“Deeply Personal”: The Aussie Chocolatiers Going Beyond Milk and Dark Chocolate
From a Wiradjuri woman using native ingredients to a former Bibelot chef’s Japanese and Filipino creations, these artisans ...
CURE13h
BELLA Clinical Trial Initiated in Platinum-Resistant Ovarian Cancer
The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ...
Corcept Therapeutics initiates trial of Phase 2 trial BELLA
Corcept Therapeutics (CORT) announced the start of BELLA, a Phase 2 trial of relacorilant plus nab-paclitaxel and bevacizumab evaluating ...
Zacks.com on MSN6d
CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal
The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian ...
Experimental women's cancer drug boosts survival rates in notable study
A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.
Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...
Corcept Therapeutics Stock (CORT) Rockets Up 100% After Groundbreaking Cancer Trial Success
Corcept Therapeutics (CORT) stock shot up over 100% yesterday as markets reacted to the company’s announcement of promising outcomes from its ...
The Mad Butcher tells John about his struggles with education and pushing Sir Tim Shadbolt off a wharf
Born in Wellington in 1944, Peter struggled at school with what would now be recognised as dyslexia. He left Wellington Tech at age 15 and worked as a tele ...